EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET 2019-2027

Lifesciences | Diagnostic & Biotechnology

EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET 2019-2027

Market By Gender, End-use And Geography | Forecast 2019-2027

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

Triton Research predicts that the Europe infertility (testing and treatment) market is anticipated to grow at a CAGR of 6.69% in terms of revenue during the years 2019-2027.

Countries studied in the Europe infertility (testing and treatment) market include:

•           The United Kingdom

•           Germany

•           France

•           Italy

•           Spain

•           Russia

•           Rest of Europe

Report scope can be customized per your requirements. Request For Customization

The average expense for IVF treatment in Europe relatively affordable, which attracts infertility patients from around the world. Organizations are now investing in the European region. Couples seeking infertility treatment are now heading to The Czech Republic as the country is known to provide these treatments at lower costs. The clinics in the country are well-regulated, and their success rates can be compared to Spain when it comes to egg donation.

The market definition, key insights, Porter’s five force analysis, and the current trends in infertility (testing and treatment) market have been discussed in detail by Triton in the report.

IVF and infertility are grave issues that concern the women of England and Britain. National Health Service in England is the major funding agency of most of the IVF cases in the UK. It is known to fund a significant percentage of the IVF cycles in England and Wales with more than half the people paying themselves. Moreover, IVF is an expensive cycle and requires an average of four cycles to work. This has greatly impacted the number of women opting for IVF and is impacting the growth of the market. However, the IVF market in the UK has a significant share as compared to other countries in the region. There are various regulations for opting IVF in the UK. The Human Fertilisation and Embryology Authority (HFEA) regulate IVF in the UK allows embryo freezing, egg and sperm donation and embryo screening for inherited diseases. It has also recently approved the use of hybrid embryos for medical research.

Computer-assisted semen analysis (CASA) is one of the methods of male infertility testing. Earlier methods analyzed semen by calculating the volume and determined sperm counts through microscopy. CASA uses digital images from a microscope which provide an accurate and clear picture of the semen for sperm evaluation. Characteristics measured in normal semen analysis pertain to the quality of semen only. Computer-assisted semen analysis involves less complexity and time as compared to normal semen analysis. CASA follows the WHO criteria for the assessment of sperms. Computer-assisted semen analysis systems are capable of removing non-sperm cells from the analysis just by the click of a mouse. This reduces the errors and provides reliable motility analysis and concentration. Thus, CASA provides more accurate results in lesser time.

 

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1.    INFERTILITY (TESTING AND TREATMENT) MARKET - SUMMARY

2.    INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. KEY INSIGHTS

2.2.1.   IVF DOMINATES THE FEMALE TREATMENT MARKET

2.2.2.   OXIDATIVE STRESS ANALYSIS IS THE FASTEST GROWING MALE INFERTILITY TESTING MARKET

2.3. PORTER’S FIVE FORCE ANALYSIS

2.3.1.   THREAT OF NEW ENTRANTS

2.3.2.   THREAT OF SUBSTITUTE

2.3.3.   BARGAINING POWER OF BUYERS

2.3.4.   BARGAINING POWER OF SUPPLIERS

2.3.5.   INTENSITY OF COMPETITIVE RIVALRY

2.4. KEY IMPACT ANALYSIS

2.4.1.   TREATMENT OPTIONS

2.4.2.   QUALITY OF MEDICAL PROCEDURES

2.4.3.   PRICE OF TREATMENTS

2.4.4.   SHIFT TOWARDS MEDICAL TOURISM

2.4.5.   REIMBURSEMENT

2.5. MARKET ATTRACTIVENESS INDEX

2.6. VENDOR SCORECARD

2.7. INDUSTRY COMPONENTS

2.7.1.   RAW MATERIAL PROCUREMENT

2.7.2.   MANUFACTURING

2.7.3.   SUPPLY LOGISTICS

2.7.4.   DISTRIBUTION CHANNELS

2.7.5.   END-USERS

2.8. REGULATORY FRAMEWORK

2.9. MARKET DRIVERS

2.9.1.   RISE IN INFERTILITY AND TREATMENT AWARENESS

2.9.2.   MEDICAL TOURISM IN FERTILITY TREATMENTS

2.9.3.   SURROGACY LAWS ARE GETTING MORE DEFINED

2.9.4.   HEALTHCARE ADVANCES HAVE FINE-TUNED FERTILITY TREATMENT

2.9.5.   INCREASING EFFECTIVENESS OF TREATMENTS

2.9.6.   HEALTHIER DONOR EGGS

2.9.7.   INTRODUCTION OF NEW TESTING DEVICES

2.10.            MARKET RESTRAINTS

2.10.1.                TREATMENT PROCEDURE OUT OF REACH FOR MANY DUE TO HIGH COSTS

2.10.2.                COUNTRY-WISE REGULATORY ISSUES

2.11.            MARKET OPPORTUNITIES

2.11.1.                REDUCING THE COST OF TREATMENT TO MAKE IT MORE ACCESSIBLE

2.11.2.                IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS

2.11.3.                DIY TESTING INCREASING ACCESS AND REDUCING COST

2.12.            MARKET CHALLENGES

2.12.1.                INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN

2.12.2.                PERILS OF MULTIPLE PREGNANCIES

2.12.3.                TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE FOR INFERTILITY TREATMENTS

3.    INFERTILITY (TESTING AND TREATMENT) MARKET OUTLOOK - BY GENDER

3.1. MALE GENDER

3.1.1.   TESTING

3.1.1.1.      DNA FRAGMENTATION

3.1.1.2.      OXIDATIVE STRESS ANALYSIS

3.1.1.3.      SPERM PENETRATION ASSAY

3.1.1.4.      COMPUTER-ASSISTED SEMEN ANALYSIS (CASA)

3.1.1.5.      SPERM AGGLUTINATION

3.1.1.6.      MICROSCOPIC EXAMINATION

3.1.1.7.      OTHERS

3.1.2.   TREATMENT

3.2. FEMALE GENDER

3.2.1.   FEMALE INFERTILITY TESTING

3.2.1.1.      OVULATION TESTING

3.2.1.2.      HYSTEROSALPINGOGRAPHY

3.2.1.3.      LAPAROSCOPY

3.2.1.4.      TRANSVAGINAL ULTRASOUND

3.2.1.5.      OVARIAN RESERVE TESTING

3.2.1.6.      HORMONAL LEVEL TESTING

3.2.1.7.      OTHERS

3.2.2.   TREATMENT

4.    INFERTILITY (TESTING AND TREATMENT) MARKET OUTLOOK - BY END-USE

4.1. FERTILITY CLINICS

4.2. HOSPITALS

4.3. SURGICAL CENTERS

4.4. CLINICAL RESEARCH INSTITUTES

5.    INFERTILITY (TESTING AND TREATMENT) MARKET - REGIONAL OUTLOOK

5.1.      UNITED KINGDOM

5.2.      GERMANY

5.3.      FRANCE

5.4.      SPAIN

5.5.      ITALY

5.6.      RUSSIA

5.7.      REST OF EUROPE

6.    COMPETITIVE LANDSCAPE

6.1. ANDROLOGY SOLUTIONS

6.2. ENDO PHARMACEUTICALS

6.3. PROGYNY

6.4. FERRING PHARMACEUTICALS

6.5. GENEA

6.6. HALOTECH DNA

6.7. IRVINE SCIENTIFIC

6.8. MERCK

6.9. ORIGIO

6.10.            OVASCIENCE

6.11.            VITROLIFE AB        

6.12.            THERMO FISHER SCIENTIFIC, INC.

6.13.            THE COOPER COMPANIES, INC.

6.14.            QUEST DIAGNOSTIC

6.15.            ESCO MICRO PTE. LTD.

7.    RESEARCH METHODOLOGY & SCOPE

7.1. RESEARCH SCOPE & DELIVERABLES

7.1.1.   OBJECTIVES OF STUDY

7.2. SOURCES OF DATA

7.2.1.   PRIMARY DATA SOURCES

7.2.2.   SECONDARY DATA SOURCES

7.3. RESEARCH METHODOLOGY

7.3.1.   EVALUATION OF PROPOSED MARKET

7.3.2.   IDENTIFICATION OF DATA SOURCES

7.3.3.   ASSESSMENT OF MARKET DETERMINANTS

7.3.4.   DATA COLLECTION

7.3.5.   DATA VALIDATION & ANALYSIS

List of table

TABLE 1:       EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)

TABLE 2:       MARKET ATTRACTIVENESS INDEX

TABLE 3:       VENDOR SCORECARD

TABLE 4:       REGULATORY FRAMEWORK

TABLE 5:       AVERAGE COST COMPARISON OF INFERTILITY TREATMENTS

TABLE 6:       EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)

TABLE 7:       EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY GENDER, 2019-2027 (IN $ MILLION)

TABLE 8:       EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY MALE GENDER, 2019-2027 (IN $ MILLION)

TABLE 9:       EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY MALE INFERTILITY TESTING, 2019-2027 (IN $ MILLION)

TABLE 10:     EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY FEMALE GENDER, 2019-2027 (IN $ MILLION)

TABLE 11:     EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY FEMALE INFERTILITY TESTING, 2019-2027 (IN $ MILLION)

TABLE 12:     EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY END-USE, 2019-2027 (IN $ MILLION)

TABLE 13:     COST OF IVF IN RUSSIA

List of Figures

FIGURE 1:     EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY END-USER, 2018 & 2027 (IN %)

FIGURE 2:     PORTER’S FIVE FORCE ANALYSIS

FIGURE 3:     KEY BUYING IMPACT ANALYSIS

FIGURE 4:     INDUSTRY COMPONENTS

FIGURE 5:     MAJOR FERTILITY TREATMENT DESTINATION RANKING

FIGURE 6:     CLINICAL ALGORITHM FOR THE EVALUATION OF INFERTILE WOMAN

FIGURE 7:     RATE OF MULTIPLE DELIVERIES

FIGURE 8:     EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY MALE GENDER, 2019-2027 (IN $ MILLION)

FIGURE 9:     EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY TESTING, 2019-2027 (IN $ MILLION)

FIGURE 10:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY DNA FRAGMENTATION, 2019-2027 (IN $ MILLION)

FIGURE 11:  CAUSES OF SPERM DNA FRAGMENTATION

FIGURE 12:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY OXIDATIVE STRESS ANALYSIS, 2019-2027 (IN $ MILLION)

FIGURE 13:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY SPERM PENETRATION ASSAY, 2019-2027 (IN $ MILLION)

FIGURE 14:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY COMPUTER-ASSISTED SEMEN ANALYSIS, 2019-2027 (IN $ MILLION)

FIGURE 15:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY SPERM AGGLUTINATION, 2019-2027 (IN $ MILLION)

FIGURE 16:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY MICROSCOPIC EXAMINATION, 2019-2027 (IN $ MILLION)

FIGURE 17:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY OTHERS, 2019-2027 (IN $ MILLION)

FIGURE 18:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY TREATMENT, 2019-2027 (IN $ MILLION)

FIGURE 19:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY FEMALE GENDER, 2019-2027 (IN $ MILLION)

FIGURE 20:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY FEMALE INFERTILITY TESTING, 2019-2027 (IN $ MILLION)

FIGURE 21:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY OVULATION TESTING, 2019-2027 (IN $ MILLION)

FIGURE 22:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY HYSTEROSALPINGOGRAPHY, 2019-2027 (IN $ MILLION)

FIGURE 23:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY LAPAROSCOPY, 2019-2027 (IN $ MILLION)

FIGURE 24:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY TRANSVAGINAL ULTRASOUND, 2019-2027 (IN $ MILLION)

FIGURE 25:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY OVARIAN RESERVE TESTING, 2019-2027 (IN $ MILLION)

FIGURE 26:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY HORMONAL LEVEL TESTING, 2019-2027 (IN $ MILLION)

FIGURE 27:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY OTHERS, 2019-2027 (IN $ MILLION)

FIGURE 28:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY FEMALE INFERTILITY TREATMENT, 2019-2027 (IN $ MILLION)

FIGURE 29:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY FERTILITY CLINICS, 2019-2027 (IN $ MILLION)

FIGURE 30:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY HOSPITALS, 2019-2027 (IN $ MILLION)

FIGURE 31:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY SURGICAL CENTERS, 2019-2027 (IN $ MILLION)

FIGURE 32:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, BY CLINICAL RESEARCH INSTITUTES, 2019-2027 (IN $ MILLION)

FIGURE 33:  EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, REGIONAL OUTLOOK, 2018 & 2027 (IN %)

FIGURE 34:  UNITED KINGDOM INFERTILITY (TESTING AND TREATMENT) MARKET, 2019-2027 (IN $ MILLION)

FIGURE 35:  FERTILITY TREATMENT IN 2014

FIGURE 36:  GERMANY INFERTILITY (TESTING AND TREATMENT) MARKET, 2019-2027 (IN $ MILLION)

FIGURE 37:  FRANCE INFERTILITY (TESTING AND TREATMENT) MARKET, 2019-2027 (IN $ MILLION)

FIGURE 38:  SPAIN INFERTILITY (TESTING AND TREATMENT) MARKET, 2019-2027 (IN $ MILLION)

FIGURE 39:  ITALY INFERTILITY (TESTING AND TREATMENT) MARKET, 2019-2027 (IN $ MILLION)

FIGURE 40:  RUSSIA INFERTILITY (TESTING AND TREATMENT) MARKET, 2019-2027 (IN $ MILLION)

FIGURE 41:  REST OF EUROPE INFERTILITY (TESTING AND TREATMENT) MARKET, 2019-2027 (IN $ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;